中危非肌层浸润性膀胱癌的最佳膀胱镜监测强度

doi:10.19723/j.issn.1671-167X.2022.04.014

摘要/Abstract

摘要：

目的: 为中危非肌层浸润性膀胱癌确定最佳的膀胱镜监测频率方法: 回顾性分析2001年1月至2019年10月于北京大学人民医院行经尿道膀胱肿瘤电切术的中危非肌层浸润性膀胱癌患者，收集患者的临床、病理学和随访资料。术后2年每3至6个月对患者进行膀胱镜检测，根据患者复发和进展的情况，在术后2年假设3种强度的监测策略：模式1：间隔3个月，模式2：间隔6个月，模式3：间隔12个月，比较3种模式间检测复发和进展的延迟个数和时间差异。结果: 共纳入185例患者，其中男性144例(77.8%)，女性41例(22.2%)，中位年龄68 (59~76)岁。单发肿瘤有118例(63.8%)，多发肿瘤有67例(36.2%)。术后病理Ta期179例(96.8%)，T1期有6例(3.2%)。高级别病变108例(58.4%)，低级别病变77例(41.6%)。在术后2年随访期间内，52例(28.1%)患者出现复发，133例(71.9%)未出现复发；11例(5.9%)患者发生进展，174例(94.1%)未发生进展。相比于模式1，模式2出现复发检测延迟的个数为29例(55.8%)，模式3为41例(78.8%)，两者之间差异有统计学意义(P=0.012)。模式1、模式2和模式3检测复发的中位延迟时间分别为1.00、1.99和4.19个月。模式1与模式2和模式3之间差异均有统计学意义(P=0.001, P=0.013)。与模式1相比，模式2出现进展检测延迟的个数为5例(45.4%)，模式3为8例(72.7%)，两者之间差异无统计学意义。模式1、模式2和模式3检测进展的中位延迟时间分别为1.00、2.00和3.00个月，三者之间差异无统计学意义。结论: 6个月间隔的膀胱镜检测模式与3个月相比，虽然会稍微延迟检测到肿瘤复发和进展，但不会造成严重的不良结局，并能够减少患者的痛苦和经济负担，在中危非肌层浸润性膀胱癌是可行的。

关键词: 膀胱癌, 膀胱镜, 随访, 监测强度

Abstract:

Objective: To determine the optimal cystoscopic frequency for intermediate-risk non-muscle invasive bladder cancer. Methods: Patients with intermediate-risk non-muscle invasive bladder cancer, who underwent transurethral resection of bladder tumor in Peking University People's Hospital from January 2001 to October 2019, were retrospectively analyzed. Their clinical, pathological and follow-up data were collected. In postoperative 2-year period, the patients were underwent cystoscopy every 3 to 6 months. Depending on recurrence and progression of the patients, we hypothesized three strategies of surveillance intensity in the first 2 years after surgery: model 1: 3-month intervals, model 2: 6-month intervals, and model 3: 12-month intervals. The differences in the numbers and time of delayed detection of recurrence and progression were compared among the three models. Results: A total of 185 patients were enrolled, including 144 males (77.8%) and 41 females (22.2%). The median age was 68 (59-76) years. There were 118 cases (63.8%) with single tumor and 67 cases (36.2%) with multiple tumor. Of the patients 179 (96.8%) had stage Ta and 6 (3.2%) had stage T1. There were 108 cases (58.4%) with high-grade disease and 77 cases (41.6%) with low-grade disease. During the follow-up period of the first 2 years, 52 patients (28.1%) had recurrence, 133 cases (71.9%) had no recurrence, 11 cases (5.9%) had progression and 174 cases (94.1%) had no progression. Compared with model 1, 29 (55.8%) delayed detection of recurrence in model 2 vs. 41 (78.8%) delayed detection of recurrence in model 3, and the difference was statistically significant (P=0.012). The median delayed time of detecting recurrence was 1.00 months in model 1, 1.99 months in model 2 and 4.19 months in model 3, respectively. There were statistically significant differences between mode 1 and model 3 (P=0.001), and between model 2 and model 3 (P=0.013). Compared with model 1, 5 (45.4%) delayed detection of progression in model 2 vs. 8 (72.7%) delayed detection of progression in model 3, and the difference was not statistically significant. The median delayed time of detecting progression was 1.00 month in model 1, 2.00 months in model 2 and 3.00 months in model 3, respectively. There was no statistically significant difference among them. Conclusion: Although providing slightly slower detection of tumor recurrence and progression, compared with 3-month intervals of cystoscopy, 6-month intervals do not result in serious adverse outcomes and reduce cost and pain of the patients, which is feasible in intermediate-risk non-muscle invasive bladder cancer.

Key words: Bladder cancer, Cystoscopy, Follow-up, Surveillance intensity

中图分类号:

R737.1

王飞,秦彩朋,杜依青,刘士军,李清,徐涛. 中危非肌层浸润性膀胱癌的最佳膀胱镜监测强度[J]. 北京大学学报（医学版）, 2022, 54(4): 669-673.

Fei WANG,Cai-peng QIN,Yi-qing DU,Shi-jun LIU,Qing LI,Tao XU. Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer[J]. Journal of Peking University (Health Sciences), 2022, 54(4): 669-673.

图/表 5

表1

图1

图2

图3

图4

参考文献 20

1	李辉章, 郑荣寿, 杜灵彬, 等. 中国膀胱癌流行现状与趋势分析[J]. 中华肿瘤杂志, 2021, 43 (3): 6.
2	陈晓芳, 陈万青, 周薇薇, 等. 2013年中国膀胱癌发病和死亡流行状况分析[J]. 中国肿瘤, 2018, 27 (2): 5.
3	Kamat AM , Hahn NM , Efstathiou JA , et al. Bladder cancer[J]. Lancet, 2016, 388 (10061): 2796. doi: 10.1016/S0140-6736(16)30512-8
4	Babjuk M , Burger M , Compérat EM , et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ): 2019 update[J]. Eur Urol, 2019, 76 (5): 639- 657. doi: 10.1016/j.eururo.2019.08.016
5	Rhijn B , Burger M , Lotan Y , et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemio-logy to treatment strategy[J]. Eur Urol, 2009, 56 (3): 430- 442. doi: 10.1016/j.eururo.2009.06.028
6	Burger M , Catto JW , Dalbagni G , et al. Epidemiology and risk factors of urothelial bladder cancer[J]. Eur Urol, 2013, 63 (2): 234- 241. doi: 10.1016/j.eururo.2012.07.033
7	Chang SS , Boorjian SA , Chou R , et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline[J]. J Urol, 2016, 196 (4): 1021- 1029. doi: 10.1016/j.juro.2016.06.049
8	Ritch CR , Velasquez MC , Kwon D , et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort[J]. J Urol, 2020, 203 (3): 505- 511. doi: 10.1097/JU.0000000000000593
9	Han C , Mengual L , Kang B , et al. Validation of urine-based gene classifiers for detecting bladder cancer in a chinese study[J]. J Cancer, 2018, 9 (17): 3208- 3215. doi: 10.7150/jca.24506
10	Zhu CZ , Ting HN , Ng KH , et al. A review on the accuracy of bladder cancer detection methods[J]. J Cancer, 2019, 10 (17): 4038- 4044. doi: 10.7150/jca.28989
11	Nielsen ME , Smith AB , Meyer AM , et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006[J]. Cancer, 2014, 120 (1): 86- 95. doi: 10.1002/cncr.28397
12	Martin DT , Shen H , Steinbach-Rankins JM , et al. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target[J]. Mol Cancer Ther, 2018, 18 (2): 413- 420.
13	Mason SJ , Downing A , Wright P , et al. Health-related quality of life after treatment for bladder cancer in England[J]. Br J Can-cer, 2018, 118 (11): 1518- 1528. doi: 10.1038/s41416-018-0084-z
14	Kamat AM , Witjes JA , Brausi M , et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer[J]. J Urol, 2014, 192 (2): 305- 315. doi: 10.1016/j.juro.2014.02.2573
15	Bhat A , Kwon D , Soodana-Prakash N , et al. Surveillance intensity in intermediate risk nonmuscle invasive bladder cancer: revisiting the optimal timing and frequency of cystoscopy[J]. J Urol, 2021, 206 (1): 22- 28. doi: 10.1097/JU.0000000000001689
16	Soria F , D'Andrea D , Abufaraj M , et al. Stratification of intermediate-risk non-muscle-invasive bladder cancer patients: implications for adjuvant therapies[J]. Eur Urol Focus, 2021, 7 (3): 566- 573. doi: 10.1016/j.euf.2020.05.004
17	Kohada Y , Ha Yashi T , Hsi RS , et al. Recurrence and progression free survival of intermediate risk non-muscle invasive bladder cancer: the impact of conditional evaluation and sub-classification[J]. BJU Int, 2021, 127 (4): 473- 485. doi: 10.1111/bju.15209
18	Fukushima H , Moriyama S , Waseda Y , et al. Significance of bladder neck involvement in risk substratification of intermediate-risk non-muscle-invasive bladder cancer[J]. Eur Urol Focus, 2021, 7 (2): 366- 372. doi: 10.1016/j.euf.2020.01.006
19	Reyes RM , Rios E , Barney S , et al. A randomized feasibility trial comparing surveillance regimens for patients with low and low-intermediate risk non-muscle invasive bladder cancer[J]. Bladder Cancer, 2021, 7 (3): 285- 295. doi: 10.3233/BLC-201535
20	Wallace D , Bryan RT , Dunn JA , et al. Delay and survival in bladder cancer[J]. BJU Int, 2015, 89 (9): 868- 878.

相关文章 15

[1]	戴翔,左美妮,张晓鹏,胡浩,徐涛. 经皮肾镜术中不同憩室颈部处理方式治疗肾盏憩室结石的长期预后[J]. 北京大学学报（医学版）, 2021, 53(4): 704-709.
[2]	王明瑞,王起,胡浩,赖金惠,贺永新,熊杰,刘献辉,刘士军,许克新,徐涛. 标准通道经皮肾镜取石术治疗孤立肾肾结石的长期安全性和有效性[J]. 北京大学学报（医学版）, 2020, 52(4): 663-666.
[3]	李玉慧,苏波,林福安,费雅楠,于笑霞,范文强,陈海英,张学武,贾园. 银屑病关节炎患者就医行为及治疗现状的多中心调查[J]. 北京大学学报（医学版）, 2019, 51(6): 1014-1018.
[4]	黄海文,闫兵,尚美霞,刘漓波,郝瀚,席志军. 女性膀胱癌患者腹腔镜膀胱全切术与开放膀胱全切术的倾向性评分匹配比较[J]. 北京大学学报（医学版）, 2019, 51(4): 698-705.
[5]	杨飞龙,洪锴,赵国江,刘承,宋一萌,马潞林. 基于长链非编码RNA的生物信息学分析构建膀胱癌预后模型并确定预后生物标志物[J]. 北京大学学报（医学版）, 2019, 51(4): 615-622.
[6]	覃子健，毕海，马潞林，黄毅，张帆. 肠代膀胱内原发肠源性腺癌1例[J]. 北京大学学报(医学版), 2018, 50(4): 737-739.
[7]	唐兴国，颜野，邱敏，卢剑，陆敏，侯小飞，黄毅，马潞林. 单中心16年青年膀胱尿路上皮癌患者的诊治[J]. 北京大学学报(医学版), 2018, 50(4): 630-633.
[8]	张海东，张立，释栋，韩劼，闫夏，谢也斯，孟焕新. 锥形锁柱种植体用于因牙周炎缺牙患者修复的临床观察[J]. 北京大学学报(医学版), 2018, 50(2): 300-307.
[9]	叶海云，许清泉，黄晓波，马凯，王晓峰. 卡介苗膀胱灌注治疗致结核性前列腺脓肿1例[J]. 北京大学学报(医学版), 2015, 47(6): 1039-1041.
[10]	姚林, 张雷, 范宇, 张政, 徐燕鹏, 刘茗洁, 何志嵩, 龚侃, 李学松, 张争, 张崔健, 周利群. 前瞻随机对照研究：新技术对硬性膀胱镜患者舒适度的提高[J]. 北京大学学报（医学版）, 2014, 46(4): 635-637.
[11]	沈棋, 胡帅, 李峻, 王静华, 何群. 膀胱前列腺切除术中前列腺偶发癌发生率及临床病理特点分析[J]. 北京大学学报（医学版）, 2014, 46(4): 515-518.
[12]	邵光军，蔡林，李学松，宋刚，李雪迎，何志嵩，周利群. 脐尿管癌：单中心30年经验总结[J]. 北京大学学报（医学版）, 2013, 45(5): 774-778.
[13]	郑卫, 吴鑫, 张雷, 宋刚, 张争, 龚侃, 宋毅, 李学松, 何志嵩, 周利群. 腹腔镜膀胱全切手术：单中心60例学习曲线结果分析[J]. 北京大学学报（医学版）, 2012, 44(4): 558-562.
[14]	张崔建 , 李学松 , 虞巍 , 吴问汉, 何志嵩 , 金杰 , 周利群. 成人肾母细胞瘤的治疗及其长期随访结果[J]. 北京大学学报（医学版）, 2012, 44(4): 535-538.
[15]	石宇红, 李茹 , 陈适 , 苏茵 , 贾园. 91例混合性结缔组织病患者的临床特点及转归[J]. 北京大学学报（医学版）, 2012, 44(2): 270-274.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Variables	n	%
All patients	185	100.0
Gender
Female	41	22.2
Male	144	77.8
Age/years
≤65	82	44.3
＞65	103	55.7
Smoking history
No	132	71.4
Yes	53	28.6
Tumor number
1	118	63.8
2	31	16.8
3	12	6.5
4	3	1.6
5	2	1.0
＞5	19	11.3
Tumor size
≤3 cm	166	89.7
＞3 cm	13	7.0
Unknown	6	3.3
T stage
T1	6	3.2
Ta	179	96.8
Grade
LG	77	41.6
HG	108	58.4
Immediate single instillation
No	54	29.2
Yes	131	70.8
Adjuvant intravesical therapy
Epirubicin	30	16.2
Pirarubicin	118	63.8
Other	13	7.0
Unknown	24	13.0